{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:17:50Z","timestamp":1763389070078,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T00:00:00Z","timestamp":1489363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"publisher","award":["PRA-2015"],"award-info":[{"award-number":["PRA-2015"]}],"id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009888","name":"Regione Toscana","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009888","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00280-017-3271-3","type":"journal-article","created":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T22:22:33Z","timestamp":1489443753000},"page":"767-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Association of the hOCT1\/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia"],"prefix":"10.1007","volume":"79","author":[{"given":"Laura","family":"Galeotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ceccherini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Laurino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marialuisa","family":"Polillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2661-6183","authenticated-orcid":false,"given":"Antonello","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Barat\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Fava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Cervetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Fontanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Ciabatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Arrigoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvio","family":"Cornolti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,13]]},"reference":[{"key":"3271_CR1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054\u20131061","journal-title":"Leukemia"},{"key":"3271_CR2","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP et al (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26:2197\u20132203","journal-title":"Leukemia"},{"key":"3271_CR3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G et al (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494\u2013500","journal-title":"Blood"},{"key":"3271_CR4","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096\u20132102","journal-title":"Leukemia"},{"key":"3271_CR5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C et al (2012) Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30:232\u2013238","journal-title":"J Clin Oncol"},{"key":"3271_CR6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.critrevonc.2013.12.010","volume":"90","author":"M Breccia","year":"2014","unstructured":"Breccia M, Alimena G, Baccarani M et al (2014) Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11\u201312, 2013. Crit Rev Oncol Hematol 90:181\u2013189","journal-title":"Crit Rev Oncol Hematol"},{"key":"3271_CR7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884","journal-title":"Blood"},{"key":"3271_CR8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.leukres.2010.10.027","volume":"35","author":"T Tauchi","year":"2011","unstructured":"Tauchi T, Kizaki M, Okamoto S et al (2011) Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res 35:585\u2013590","journal-title":"Leuk Res"},{"key":"3271_CR9","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"AR Ibrahim","year":"2011","unstructured":"Ibrahim AR, Eliasson L, Apperley JF et al (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117:3733\u20133736","journal-title":"Blood"},{"key":"3271_CR10","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.leukres.2009.08.005","volume":"34","author":"A Awidi","year":"2010","unstructured":"Awidi A, Salem, II, Najib N et al (2010) Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods\u2019 comparison. Leuk Res 34:714\u2013717","journal-title":"Leuk Res"},{"key":"3271_CR11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11596990-000000000-00000","volume":"51","author":"V Gotta","year":"2012","unstructured":"Gotta V, Widmer N, Montemurro M et al (2012) Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. Clin Pharmacokinet 51:187\u2013201","journal-title":"Clin Pharmacokinet"},{"key":"3271_CR12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2147\/DDDT.S42902","volume":"7","author":"VM Rezende","year":"2013","unstructured":"Rezende VM, Rivellis A, Novaes MM et al (2013) Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays. Drug Des Devel Ther 7:699\u2013710","journal-title":"Drug Des Devel Ther"},{"key":"3271_CR13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","volume":"97","author":"F Guilhot","year":"2012","unstructured":"Guilhot F, Hughes TP, Cortes J et al (2012) Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica 97:731\u2013738","journal-title":"Haematologica"},{"key":"3271_CR14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000336244","volume":"127","author":"JS Zhong","year":"2012","unstructured":"Zhong JS, Meng FY, Xu D (2012) Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients. Acta Haematol 127:221\u2013227","journal-title":"Acta Haematol"},{"key":"3271_CR15","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3109\/10428194.2011.563885","volume":"52","author":"SK Sohn","year":"2011","unstructured":"Sohn SK, Oh SJ, Kim BS et al (2011) Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leuk Lymphoma 52:1024\u20131029","journal-title":"Leuk Lymphoma"},{"key":"3271_CR16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","volume":"33","author":"DL Forrest","year":"2009","unstructured":"Forrest DL, Trainor S, Brinkman RR et al (2009) Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 33:271\u2013275","journal-title":"Leuk Res"},{"key":"3271_CR17","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00277-011-1394-x","volume":"91","author":"E Faber","year":"2012","unstructured":"Faber E, Friedeck\u00fd D, Mi\u010dov\u00e1 K et al (2012) Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Ann Hematol 91:923\u2013929","journal-title":"Ann Hematol"},{"key":"3271_CR18","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1124\/jpet.105.099929","volume":"317","author":"M Saborowski","year":"2006","unstructured":"Saborowski M, Kullak-Ublick GA, Eloranta JJ (2006) The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha. J Pharmacol Exp Ther 317:778\u2013785","journal-title":"J Pharmacol Exp Ther"},{"key":"3271_CR19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/jcp.20081","volume":"201","author":"G Ciarimboli","year":"2004","unstructured":"Ciarimboli G, Struwe K, Arndt P et al (2004) Regulation of the human organic cation transporter hOCT1. J Cell Physiol 201:420\u2013428","journal-title":"J Cell Physiol"},{"key":"3271_CR20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/tpj.2014.7","volume":"14","author":"A Di Paolo","year":"2014","unstructured":"Di Paolo A, Polillo M, Capecchi M et al (2014) The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics J 14:328\u2013335","journal-title":"Pharmacogenomics J"},{"key":"3271_CR21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2012.066480","volume":"98","author":"S Angelini","year":"2013","unstructured":"Angelini S, Soverini S, Ravegnini G (2013) Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 98:193\u2013200","journal-title":"Haematologica"},{"key":"3271_CR22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/ejh.12235","volume":"92","author":"M Koren-Michowitz","year":"2014","unstructured":"Koren-Michowitz M, Buzaglo Z, Ribakovsky E et al (2014) OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients. Eur J Haematol 92:283\u2013288","journal-title":"Eur J Haematol"},{"key":"3271_CR23","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/leu.2015.170","volume":"29","author":"DB Watkins","year":"2015","unstructured":"Watkins DB, Hughes TP, White DL (2015) OCT1 and imatinib transport in CML: is it clinically relevant? Leukemia 29:1960\u20131969","journal-title":"Leukemia"},{"key":"3271_CR24","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3892\/ol.2014.1857","volume":"7","author":"D Vivona","year":"2014","unstructured":"Vivona D, Lima LT, Rodrigues AC et al (2014) ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncol Lett 7:1313\u20131319","journal-title":"Oncol Lett"},{"key":"3271_CR25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.biopha.2014.01.009","volume":"68","author":"A Au","year":"2014","unstructured":"Au A, Aziz Baba A, Goh AS et al (2014) Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients. Biomed Pharmacother 68:343\u2013349","journal-title":"Biomed Pharmacother"},{"key":"3271_CR26","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","volume":"15","author":"DH Kim","year":"2009","unstructured":"Kim DH, Sriharsha L, Xu W et al (2009) Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 15:4750\u20134758","journal-title":"Clin Cancer Res"},{"key":"3271_CR27","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","volume":"14","author":"A Petain","year":"2008","unstructured":"Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Georger B, Barrois M, S\u00e9ronie-Vivien S, LeCesne A, Vassal G, Innovative therapies with Children with Cancer European Consortium (2008) Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 14:7102\u20137109","journal-title":"Clin Cancer Res"},{"key":"3271_CR28","unstructured":"The R Project for Statistical Computing. http:\/\/www.r-project.org"},{"key":"3271_CR29","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1200\/JCO.2014.56.0904","volume":"32","author":"H Kantarjian","year":"2014","unstructured":"Kantarjian H, Cortes JE (2014) Complete Cytogenetic Response, not Deep Molecular Response, is associated with survival in Chronic Myeloid Leukemia. J Clin Oncol 32:3077","journal-title":"J Clin Oncol"},{"key":"3271_CR30","doi-asserted-by":"crossref","first-page":"e51771","DOI":"10.1371\/journal.pone.0051771","volume":"7","author":"O Singh","year":"2012","unstructured":"Singh O, Chan JY, Lin K et al (2012) SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. PLoS ONE 7:e51771","journal-title":"PLoS ONE"},{"key":"3271_CR31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs-2016-0103","volume":"18","author":"ZP Jiang","year":"2017","unstructured":"Jiang ZP, Zhao XL, Takahashi N, Angelini S, Dubashi B, Sun L, Xu P (2017) Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics 18:35\u201356","journal-title":"Pharmacogenomics"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3271-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T17:54:17Z","timestamp":1589738057000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3271-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,13]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["3271"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3271-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2017,3,13]]}}}